Pharmacological inactivation of MYC for the treatment of cancer

Dean W Felsher; Nicole Bradon

doi:10.1358/dnp.2003.16.6.829309

Pharmacological inactivation of MYC for the treatment of cancer

Drug News Perspect. 2003 Jul-Aug;16(6):370-4. doi: 10.1358/dnp.2003.16.6.829309.

Authors

Dean W Felsher¹, Nicole Bradon

Affiliation

¹ Division of Oncology, Departments of Medicine and Pathology, Stanford University, Stanford, California, USA. dfelsher@stanford.edu

PMID: 12973448
DOI: 10.1358/dnp.2003.16.6.829309

Abstract

The overexpression of the MYC proto-oncogene has been implicated in the pathogenesis of most types of human cancer. Recent experimental observations indicate that the inactivation of MYC may be effective in the treatment of neoplasia. Several different strategies have been employed to develop novel drugs that may be effective to target the inactivation of MYC for the treatment of cancer. Some of these strategies are discussed.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Gene Expression Regulation, Neoplastic
Gene Silencing*
Genes, myc / drug effects*
Humans
Neoplasms / drug therapy*
Neoplasms / genetics
Neoplasms / metabolism
Oligonucleotides, Antisense / pharmacology
Proto-Oncogene Mas
Transcription, Genetic / drug effects

Substances

Antineoplastic Agents
MAS1 protein, human
Oligonucleotides, Antisense
Proto-Oncogene Mas